Novel drug delivery systems in management of cardiovascular diseases

  • Shyamoshree Basu B.R. Singh Hospital & Centre for Medical Education & Research
Keywords: Cardiovascular, transdermal, micelles, liposomes, nanoparticles, dendrimers, stents, balloons

Abstract

Cardiovascular (CV) diseases like atherosclerosis, angina pectoris, acute myocardial infarction, are a major cause of mortality in the whole world owing to the present day hectic lifestyle. In this review we will concentrate on the various novel drug delivery systems (DDS) like transdermal DDS, micelles, liposomes, nanoparticles (NPs), dendrimers, drug eluting stents (DES) and drug eluting balloons (DEB) that are being used over the years and in present day for the treatment of these diseases.

Author Biography

Shyamoshree Basu, B.R. Singh Hospital & Centre for Medical Education & Research

Advanced Cardiac Center,
B.R. Singh Hospital & Centre for Medical Education & Research
Kolkata, West Bengal, India

References

1. Abrams J (1989); “Transdermal nitroglycerin in angina pectoris”; European Heart Journal; 10(suppl_A); 11–19
2. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J, Saqqur M, Demchuk AM and Moye LA (2004); “Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke”; The New England Journal of Medicine; 351(21); 2170-2178.
3. Belkacemi A, Agostoni P, Voskuil M, Doevendans P, Stella P (2011); “Drug-eluting Balloons in Coronary Artery Disease - Current and Future Perspectives”; ICR; 6(2); 157-160.
4. Degertekin M, Regar E, Tanabe K, Smits PC, van der Giessen WJ, Carlier SG, de Feyter P, Vos J, Foley DP, Ligthart JM (2003); “Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience”; J. Am. Coll. Cardiol.; 41(2); 184-189.
5. Di Mario C, Griffiths H, Goktekin O, Peeters N, Verbist J, Bosiers M, Deloose K, Heublein B, Rohde R, Kasese V, Ilsley C, Erbel R (2004); “Drug-eluting bioabsorbable magnesium stent”; Journal of Interventional Cardiology; 17(6); 391-395.
6. Duan J, Yu Y, Li Y, Yu Y, Sun Z (2013); “Cardiovascular toxicity evaluation of silica nanoparticles in endothelial cells and zebrafish model”; Biomaterials; 34(23); 5853-5862.
7. Galagudza MM, Korolev DV, Sonin DL, Postnov VN, Papayan GV, Uskov IS, Belozertseva AV, Shlyakhto EV (2010); “Targeted drug delivery into reversibly injured myocardium with silica nanoparticles: Surface functionalization, natural biodistribution, and acute toxicity”; Int. J. Nanomed.; 5; 231-237
8. Kukowska-Latallo JF, Bielinska AU, Johnson J, Spindler R, Tomalia DA, Baker JR (1996); “Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers”; Proc. Natl. Acad. Sci.; 93(10); 4897-4902.
9. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ (1997); “Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model”; J. Am. Coll. Cardiol.; 29(4); 808-816.
10. Matoba T, Koga JI, Nakano K, Egashira K, Tsutsui H (2017); “Nanoparticle-mediated drug delivery system for atherosclerotic cardiovascular disease”; J Cardiol.; 70(3); 206-211.
11. Paulis LE, Geelen T, Kuhlmann MT, Coolen BF, Schafers M, Nicolay K, Strijkers GJ (2012); “Distribution of lipid-based nanoparticles to infarcted myocardium with potential application for MRI monitored drug delivery”; J. Con.Rel; 162(2); 276-285
12. Perel P., Avezum A., Huffman M., Pais P., Rodgers A., Vedanthan R., Wood D., Yusuf S (2015); “Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease”; Glob Heart;10(2); 99-110.
13. Qiao Y. et al.(2017); “PEG coated gold nanoparticles attenuate β adrenergic receptor mediated cardiac hypertrophy”; Int. J Nanomed; 12; 4709-4719.
14. Richelsen RKB, Overvad TF, Jensen SE (2016); “Drug-Eluting Balloons in the Treatment of Coronary De Novo Lesions: A Comprehensive Review”; Cardiol Ther; 5(2); 133-160
15. Rosenschein U, Roth A, Rassin T, Basan S, Laniado S, Miller HI (1997); “Analysis of coronary ultrasound thrombolysis endpoints in acute myocardial infarction (ACUTE trial) results of the feasibility phase”; Circulation; 95(6); 1411-1416.
16. Stone GW, Ellis SG, Cox DA, Hermiller J, Shaughnessy CO, Mann JT, Turco M, Caputo R, Bergin P, and Greenberg J (2004); “A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease”; N. Engl. J. Med.; 350(3); 221-231.
17. Takahama H, Minamino T, Asanuma H, Fujita M, Asai T, Wakeno M, Sasaki H, Kikuchi H, Hashimoto K, Oku N (2009); “Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats”; J. Am. Coll.Cardiol. ; 53(8); 709-717
18. Tang Y, Gan X, Cheheltani R et al. (2014); “Targeted delivery of vascular endothelial growth factor improves stem cell therapy in a rat myocardial infarction model”; Nanomedicine; 10(8); 1711-1718.
19. Virmani R, Farb A, Guagliumi G, Kolodgie FD (2004); “Drug eluting stents: Caution and concerns for long-term outcome”; Coron.Artery Dis.; 15(6); 313-318.
20. Waksman R and Pakala R (2009); “Drug-Eluting Balloon: The Comeback Kid?”; Circ Cardiovasc Interv.; 2(4); 352-358.
21. Wang Y, Bai Y, Price C, Boros P, Qin L, Bielinska AU, Kukowska-Latallo JF, Baker JR, Bromberg JS (2001); “Combination of electroporation and DNA/dendrimer complexes enhances gene transfer into murine cardiac transplants”; Am. J. Transplantation; 2001; 1(4);334-338.
22. Wieneke H, Dirsch O, Sawitowski T, Gu YL, Brauer H, Dahmen U, Fischer A, Wnendt S, Erbel R (2003); “Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits”; Cathet. Cardiovasc. Interv.; 60(3); 399-407.
23. Wissgott C, Richter A, Kamusella P, Steinkamp HJ (2007); “Treatment of critical limb ischemia using ultrasound-enhanced thrombolysis (PARES Trial): Final results”. J. Endovasc. Ther.; 14(4); 438-443.
24. Wu Y, Unger EC, McCreery TP, Sweitzer RH, Shen D, Wu G, Vielhauer MD (1998); “Binding and lysing of blood clots using MRX-408”; Invest. Radiol.; 33(12); 880-885.
25. Xingyan L, Hong L, Zhaowu Z, Weihua Z, Jianqiang L, Zhiwei H (2011); “Pharmacokinetics of ligustrazine ethosome patch in rats and anti-myocardial ischemia and anti-ischemic reperfusion injury effect”; Int J Nanomed.; 6; 1391–1398.
Published
2018-06-07
How to Cite
[1]
Basu, S. 2018. Novel drug delivery systems in management of cardiovascular diseases. PharmaTutor. 6, 6 (Jun. 2018), 19-23. DOI:https://doi.org/10.29161/PT.v6.i6.2018.19.
Section
Articles